Cargando…
Intrathecal Rituximab as a Rescue Therapy in Refractory Pure CSF Positive, Non-Teratomatous Type Anti-NMDAR Encephalitis
NMDAR antibody encephalitis is the most common autoimmune encephalitis characterized by a myriad of neuropsychiatric symptoms. It predominantly affects females and is associated with ovarian teratoma (58%). Nineteen percent do not respond to treatment and are left with serious neurological deficits....
Autores principales: | Krishnan, Parameswaran, Thomas, Kurian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764926/ https://www.ncbi.nlm.nih.gov/pubmed/36561001 http://dx.doi.org/10.4103/aian.aian_134_22 |
Ejemplares similares
-
Efficacy and Safety of Rituximab in Chinese Children With Refractory Anti-NMDAR Encephalitis
por: Dou, Xiangjun, et al.
Publicado: (2020) -
Utility of CSF Cytokine/Chemokines as Markers of Active Intrathecal Inflammation: Comparison of Demyelinating, Anti-NMDAR and Enteroviral Encephalitis
por: Kothur, Kavitha, et al.
Publicado: (2016) -
Pharmaceutical care of rituximab in the treatment of children with refractory anti-NMDAR encephalitis: A case report
por: Wu, Haiyan, et al.
Publicado: (2023) -
CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis
por: Desestret, Virginie, et al.
Publicado: (2015) -
Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis
por: Ciano-Petersen, Nicolás Lundahl, et al.
Publicado: (2023)